Resistência bacteriana: uma investigação genômica baseada em mecanismos de resistência contra a azitromicina (2019-2021)

Azithromycin, an antibiotic of the macrolide class, has been widely used due to its activity against several infectious processes involving atypical and intracellular pathogens. The indiscriminate use of this drug also contributes to the emergence of bacterial resistance. According to the World H...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Autor principal: Galvão, Izabelli Cristiane da Silva
Outros Autores: Silveira, Ivanaldo Amâncio
Formato: bachelorThesis
Idioma:pt_BR
Publicado em: Universidade Federal do Rio Grande do Norte
Assuntos:
Endereço do item:https://repositorio.ufrn.br/handle/123456789/33943
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
Descrição
Resumo:Azithromycin, an antibiotic of the macrolide class, has been widely used due to its activity against several infectious processes involving atypical and intracellular pathogens. The indiscriminate use of this drug also contributes to the emergence of bacterial resistance. According to the World Health Organization, there is an estimate that bacterial resistance will cause around 10 million deaths annually worldwide by the year 2050. Therefore, the aim of this study was to carry out a systematic review of the literature, seeking genomic information related to updates on bacterial resistance against azithromycin, through a search in the Pubmed and Scopus databases, which resulted in the selection of 24 articles from 2019 to 2021. In the proposed review, genomic information related to resistance was obtained bacterial against azithromycin, including important data on some microorganisms, such as: Neisseria gonorrhoeae, Salmonella Typhi, Streptococcus pneumoniae, Mycoplasma genitalium, which demonstrate great versatility in the development of resistance mechanisms against the aforementioned antimicrobial, through mutation and expression of genes. Several in vitro studies are underway with the participation of efflux pump inhibitors aimed at reducing resistance, with expressive results in combating this phenomenon, but which require clinical investigation to corroborate their application.